Capmatinib and Afatinib: Interaction Details

Brand names
Afatinib
Gilotrif
Capmatinib
Tabrecta
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Capmatinib With Afatinib

What can happen when they are taken together (rated Major)

Increased exposure and an increased risk of increased adverse reactions

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Exposure to P-gp substrates rises when they are given together with capmatinib, a change that may heighten the adverse reactions associated with those substrates.1 In the case of the P-gp substrate digoxin, concurrent administration with capmatinib raised the digoxin (0 to inf) by 47% and its by 74%.12 Where combined use of capmatinib with a P-gp substrate cannot be avoided and even small shifts in concentration could result in serious adverse reactions, the P-gp substrate dose should be lowered in line with recommendations.1

The Capmatinib and Afatinib Interaction, Explained

Capmatinib (Tabrecta) can slow down a "pump" in your body called that helps move afatinib (Gilotrif) out. When that pump is slowed, more afatinib may stay in your blood. That could make afatinib's common side effects stronger, like diarrhea, skin rash, mouth sores, or nail problems.

This is mostly expected from how the drugs work, not from studies of these two drugs together. Please keep taking your medicines as prescribed and tell your pharmacist or doctor about any new or worse side effects. Your care team can watch you closely and adjust your dose if needed.

Mechanism: Capmatinib inhibits -mediated efflux. Afatinib is a P-gp and is not a , so increased afatinib exposure is expected.

Magnitude: Not studied with afatinib. With digoxin, capmatinib increased (0-inf) by 47% and by 74%. Onset unspecified. Evidence: theoretical. Severity: major.

  • Avoid when feasible. If coadministration is unavoidable, reduce the afatinib dose per labeling recommendations.
  • Monitor for afatinib toxicity, including diarrhea, rash or acneiform dermatitis, stomatitis, paronychia, and .

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Capmatinib and Afatinib Interact

The likely mechanism

of -mediated efflux transport by capmatinib

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Capmatinib and Afatinib Interaction

Your care team may decide to avoid using these two medicines together when another option fits. If both are needed, they may lower your afatinib dose. The dose can be adjusted and individualized for you, and your team may monitor you more closely for side effects.

  • Keep taking both medicines exactly as prescribed. Do not change doses on your own.
  • Tell your pharmacist or prescriber that you take both medicines.
  • Report new or worsening diarrhea, rash, mouth sores, or other side effects promptly.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Capmatinib or Afatinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: TABRECTA oral tablets, capmatinib oral tablets

    When capmatinib was given together with digoxin (a ), digoxin (0 to inf) rose by 47% and rose by 74%.1 In a small prospective single-sequence study of adult patients with MET-dysregulated advanced solid tumors refractory to currently available therapies (N=32), of capmatinib and digoxin, relative to digoxin given alone, produced digoxin geometric mean ratios of 1.47 (90% CI, 1.28 to 1.68) for AUC(infinity), 1.63 (90% CI, 1.42 to 1.89) for AUC(last), and 1.74 (90% CI, 1.43 to 2.13) for Cmax.

    The t(1/2) of digoxin was likewise longer with capmatinib coadministration than with digoxin alone (61.4 vs 47 hours), whereas Tmax was unchanged. Patients received capmatinib 400 mg twice daily for 12 days, together with a single dose of digoxin 0.25 mg and rosuvastatin 10 mg on day 12.2

Capmatinib and Afatinib: Common Questions

How serious is the Capmatinib and Afatinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Capmatinib and Afatinib interaction managed?

Your care team may decide to avoid using these two medicines together when another option fits. If both are needed, they may lower your afatinib dose. The dose can be adjusted and individualized for you, and your team may monitor you more closely for side effects. Keep taking both medicines exactly as prescribed. Do not change doses on your own. Tell your pharmacist or prescriber that you take bot… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Capmatinib and Afatinib Interaction

Ask in your own words about taking Capmatinib and Afatinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: TABRECTA(TM) oral tablets, capmatinib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2020. DailyMed
  2. Grande E, Giovannini M, Marriere E, et al: Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol 2021; 87(7):2867-2878.
Was this write-up helpful?

Other Serious Interactions of Capmatinib and Afatinib

Also serious with Afatinib

Also serious with Capmatinib

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.